6 results
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
The primary objective is, in patients at low-density lipoprotein cholesterol (LDL-C) goal while on statin therapy, with established cardiovascular disease (CVD) or at high risk for CVD, and hypertriglyceridemia (fasting triglycerides [TG] *200 mg/dL…
The overall aim of the present study is to develop and test a cognitive rehabilitation intervention for OHCA patients with cognitive deficits. The intervention will be designed to improve cognitive functioning in the domains of attention, memory,…
Primary Objective: The aim of this study is to research the effect of a computerized cognitive rehabilitation program (RehaCom) in post COVID-19 patients with cognitive complaints on their sustained and divided attention and their working memory.…